ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0863

Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study

Chi Chiu Mok1, Ling Yin Ho2, Kar Li Chan3, Sau Mei TSE2 and Chi Hung To4, 1Tuen Mun Hospital, Hong Kong, China, 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Hong Kong, 4Pok Oi Hospital, Hong Kong, Hong Kong

Meeting: ACR Convergence 2021

Keywords: biomarker, Cardiovascular, Prognosis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).

Methods: Consecutive patients who fulfilled ≥4 1997 ACR criteria for SLE and consented for a biomarker study between 2009 and 2012 were included. Stored serum samples from these patients were assayed for PCSK9 using a commercial ELISA kit. New ischemic vascular events in these patients during follow-up were evaluated. ROC analysis was performed to adopt the best cut-off value of PCSK9 for the prediction of a new vascular event. Patients were divided into two groups according to this cut-off value. The cumulative incidence of new vascular event and mortality over time was studied by Kaplan-Meier’s analysis and compared between the high and low PCSK9 subgroups. Cox regression was performed to study the effect of the PCSK9 subgroups on new vascular events and mortality, adjusted for other confounding factors.

Results: 539 SLE patients were studied (93% women, age 41.9±14.0 years; disease duration 106±90.4 months at entry). The mean PCSK level at baseline was 265±158ng/ml and a cut-off of 243.25ng/ml best predicted a new vascular event by the maximum Youden’s index (ROC analysis: AUC 0.63[0.51-0.74]; sensitivity 69%; specificity 61%). 220 SLE patients had baseline PCSK9 level of ≥243.25ng/ml (high PCSK9) and 319 patients had level below 243.25ng/ml (low PCSK9). No significant difference in SLE manifestations and autoantibody profile was observed between the high and low PCSK9 groups except the former had a significantly higher prevalence of lupus nephritis. 31 new vascular events (13 ischemic stroke, 13 acute coronary syndrome and 5 peripheral vascular disease) developed in 29 patients over a mean follow-up of 91.3±18.6 months. Patients with a new vascular event had a significantly higher baseline PCSK9 level than those without (350±225 vs 260±153ng.ml; p=0.02). The cumulative incidence of a first vascular event at 5 years from study entry was 7.8% in the high PCSK9 group and 1.9% in the low PCSK9 group (log rank test; p=0.003, univariate hazard ratio [HR] 3.08[1.39-6.80]). At last follow-up, 40 patients succumbed (10 due to vascular event [vascular death]). Kaplan-Meier’s analysis showed that the high PCSK9 group had a significant higher cumulative risk of all-cause mortality (log rank test p=0.003; HR2.68[1.39-5.14]) and vascular mortality (log rank test p=0.002; HR12.4[1.56-98.4]) over time than the low PCSK9 group. Cox regression analyses showed that high PCSK9 was significantly associated with new vascular events (HR2.56[1.10-5.99]; p=0.03) independent of age, sex, SLE duration, diabetes mellitus, hypertension, body mass index, atherogenic index, smoking, antiphospholipid antibody, past history of vascular events, and the use of statins, aspirin, hydroxychloroquine, prednisolone, mycophenolate mofetil, azathioprine and the calcineurin inhibitors at study entry.

Conclusion: A higher serum PCSK9 level is a strong risk factor for ischemic vascular events in patients with SLE, which is independent of age, sex, traditional atherosclerotic risk factors, antiphospholipid antibody and the use of statins and immunosuppressive medications.


Disclosures: C. Mok, None; L. Ho, None; K. Chan, None; S. TSE, None; C. To, None.

To cite this abstract in AMA style:

Mok C, Ho L, Chan K, TSE S, To C. Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/serum-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-cardiovascular-risk-in-systemic-lupus-erythematosus-a-longitudinal-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-cardiovascular-risk-in-systemic-lupus-erythematosus-a-longitudinal-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology